Asensus Surgical Announces Collaboration with NVIDIA to Enhance Augmented Intelligence Capabilities of the ISU
07 Septembre 2023 - 12:55PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced a collaboration with NVIDIA to accelerate the
development of Asensus’s Intelligent Surgical Unit™ (ISU™) and
improve its ability to deliver novel clinical intelligence to
surgeons.
Asensus will utilize a broad suite of NVIDIA tools to enhance
the augmented intelligence capabilities of its ISU. Asensus’s ISU
is built with NVIDIA accelerated computing technology and has been
bringing real-time augmented intelligent features — such as digital
tags, 3D measurement, and enhanced camera control — to surgeons
since 2021.
“We’re thrilled to collaborate with NVIDIA to enhance the
machine vision and image analytics capabilities of the ISU, as well
as the processing speed and precision of its augmented intelligence
capabilities. Utilizing NVIDIA’s advanced technologies will allow
us to further improve the ISU’s augmented intelligence capabilities
and the roadmap of our innovative clinical applications,” said
Anthony Fernando, Asensus Surgical President and CEO. “Through this
collaboration, Asensus is furthering its vision to enhance clinical
intelligence in surgery through the use of advanced augmented
intelligence tools.”
As part of the collaboration, both companies will have early
access to relevant product roadmaps, fostering synergistic
development. Furthermore, Asensus and NVIDIA plan to jointly define
innovative business models for the development, deployment, and
commercialization of digital surgical solutions.
“The healthcare industry, and in particular digital surgery, is
becoming one of the largest data generating industries. NVIDIA
brings a domain-specific full stack edge AI computing platform,
Holoscan, to medtech innovators looking to optimize real-time data
and image processing to help solve complex problems and improve
surgeon decision-making,” said David Niewolny, Director of
Healthcare Business Development at NVIDIA. “As a leading FDA
cleared solution in soft-tissue abdominal surgery, Asensus’s ISU is
a perfect platform to leverage NVIDIA’s software-defined
architecture to accelerate innovation and deliver new products to
surgeons faster via software-as-a-medical-device applications.”
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery.
Based upon the foundations of digital laparoscopy and the
Senhance® Surgical System, the Company is developing the LUNA™
Surgical System, a next generation robotic and instrument system as
a foundation of its digital surgery solution. These systems will be
powered by the Intelligent Surgical Unit to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, augmented intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery, and digital laparoscopy with the
Senhance Surgical System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Asensus
collaboration with NVIDIA. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether utilizing NVIDIA’s advanced technologies will allow
Asensus to further improve the ISU’s augmented intelligence
capabilities and the roadmap of our innovating clinical
applications, whether Asensus’s ISU is a perfect platform to
leverage NVIDIA’s software-defined architecture to accelerate
innovation and deliver new products to surgeons faster via
software-as-a-medical-device applications and whether the
collaboration will be successful. For a discussion of the risks and
uncertainties associated with the Company’s business, please review
our filings with the Securities and Exchange Commission (SEC),
including our Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the SEC on March 2, 2023 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan VentrescaMatter
CommunicationsAsensusPR@matternow.com617-874-5488
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024